161 related articles for article (PubMed ID: 36839845)
1. Impact of Omalizumab in Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study.
Rojo-Tolosa S; González-Gutiérrez MV; Sánchez-Martínez JA; Jiménez-Gálvez G; Pineda-Lancheros LE; Gálvez-Navas JM; Jiménez-Morales A; Pérez-Ramírez C; Morales-García C
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839845
[TBL] [Abstract][Full Text] [Related]
2. Impact of Anti-IL5 Therapies on Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study.
Rojo-Tolosa S; González-Gutiérrez MV; Jiménez-Gálvez G; Sánchez-Martínez JA; Pineda-Lancheros LE; Gálvez-Navas JM; Jiménez-Morales A; Pérez-Ramírez C; Morales-García C
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768331
[TBL] [Abstract][Full Text] [Related]
3. Influence of Genetics on the Response to Omalizumab in Patients with Severe Uncontrolled Asthma with an Allergic Phenotype.
Rojo-Tolosa S; Sánchez-Martínez JA; Pineda-Lancheros LE; Gálvez-Navas JM; González-Gutiérrez MV; Jiménez-Gálvez G; Pérez-Ramírez C; Morales-García C; Jiménez-Morales A
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108192
[TBL] [Abstract][Full Text] [Related]
4. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
Norman G; Faria R; Paton F; Llewellyn A; Fox D; Palmer S; Clifton I; Paton J; Woolacott N; McKenna C
Health Technol Assess; 2013 Nov; 17(52):1-342. PubMed ID: 24267198
[TBL] [Abstract][Full Text] [Related]
6. A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment.
Davison J; Doe S
Respir Med Case Rep; 2021; 34():101557. PubMed ID: 34877251
[TBL] [Abstract][Full Text] [Related]
7. The "real-world" effectiveness and safety of omalizumab in patients with uncontrolled persistent allergic asthma in Slovakia: a subgroup analysis of the eXpeRience study.
Siracká S; Tinková LD; Hochmuth L; Leščišinová H; Hrubiško M; Dostálová K; Jeseňák M
Postepy Dermatol Alergol; 2023 Feb; 40(1):134-141. PubMed ID: 36909923
[TBL] [Abstract][Full Text] [Related]
8. Severe asthma phenotypes in patients controlled with omalizumab: A real-world study.
Campo P; Soto Campos G; Aparicio MB; Jorge AM; González Expósito HM; Quirce S; Dávila I
Respir Med; 2019 Nov; 159():105804. PubMed ID: 31704593
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study.
Pelaia C; Calabrese C; Barbuto S; Busceti MT; Preianò M; Gallelli L; Savino R; Vatrella A; Pelaia G
Pulm Pharmacol Ther; 2019 Feb; 54():25-30. PubMed ID: 30414440
[TBL] [Abstract][Full Text] [Related]
10. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
[TBL] [Abstract][Full Text] [Related]
11. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety.
Mansur AH; Srivastava S; Mitchell V; Sullivan J; Kasujee I
Respir Med; 2017 Mar; 124():36-43. PubMed ID: 28284319
[TBL] [Abstract][Full Text] [Related]
12. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.
Burch J; Griffin S; McKenna C; Walker S; Paton J; Wright K; Woolacott N
Pharmacoeconomics; 2012 Nov; 30(11):991-1004. PubMed ID: 22950547
[TBL] [Abstract][Full Text] [Related]
13. Factors reducing omalizumab response in severe asthma.
Sposato B; Scalese M; Milanese M; Masieri S; Cavaliere C; Latorre M; Scichilone N; Matucci A; Vultaggio A; Ricci A; Cresti A; Santus P; Perrella A; Paggiaro PL
Eur J Intern Med; 2018 Jun; 52():78-85. PubMed ID: 29395935
[TBL] [Abstract][Full Text] [Related]
14. [Preliminary clinical observation of omalizumab therapy for moderate to severe asthma].
Wu PH; Dong C; Xie JX; Zhang XX; Liu J; Ouyang M; Ma JJ; Huang WH; Ou CX; Li J; Zhang QL
Zhonghua Jie He He Hu Xi Za Zhi; 2021 Jul; 44(7):611-618. PubMed ID: 34256447
[No Abstract] [Full Text] [Related]
15. Omalizumab Treatment for Atopic Severe Persistant Asthma: A Single-Center, Long-Term, Real-Life Experience with 38 Patients.
Türk M; Bahçecioğlu SN; Tutar N; Oymak FS; Gülmez İ; Yılmaz İ
Turk Thorac J; 2018 Oct; 19(4):187-192. PubMed ID: 30322442
[TBL] [Abstract][Full Text] [Related]
16. Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma.
Kavati A; Zhdanava M; Ortiz B; Lecocq J; Schiffman B; Pilon D; Ho H; Lefebvre P; Stone B
Clin Ther; 2019 Oct; 41(10):1956-1971. PubMed ID: 31563391
[TBL] [Abstract][Full Text] [Related]
17. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
[TBL] [Abstract][Full Text] [Related]
18. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
Humbert M; Albers FC; Bratton DJ; Yancey SW; Liu MC; Hozawa S; Llanos JP; Kwon N
Respir Med; 2019; 154():69-75. PubMed ID: 31220806
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients.
Arrobas A; Barbosa MP; Rabiais S; Vandewalle B; Félix J
Pulmonology; 2021; 27(2):124-133. PubMed ID: 32247710
[TBL] [Abstract][Full Text] [Related]
20. Profile of patients treated with omalizumab in routine clinical practice in Spain.
Ancochea J; Chivato T; Casan P; Picado C; Herráez L; Casafont J
Allergol Immunopathol (Madr); 2014; 42(2):102-8. PubMed ID: 23267505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
